Testing A New Model For Personalized Drug Development
This article was originally published in RPM Report
Pfizer, Genentech, AstraZeneca and Amgen drugs will be studied in a lung cancer “master protocol” set to launch March 1. The trial could revolutionize the treatment of a rare, serious disease – but advocates have an even bigger goal: “changing the entire paradigm for drug development.”
You may also be interested in...
FDA Eager For More Master Protocols in Oncology: Approach Means Lower Cost For Sponsors—and Less Control
FDA officials are enthusiastic about broad, multi-agent cancer trials built on the I-SPY model. For sponsors, the trials mean less control over the development path and ultimate value proposition for the therapy—but may have important benefits on defending high prices for truly effective new therapies.
Biopharma industry is making some modest headway in quest to change the new US Medicare drug price process to treat drugs and biologics on equal footing. But eliminating the so-called ‘pill penalty’ would not on its own equalize the incentives for small molecule and large molecule R&D.
New drug pricing program under the Inflation Reduction Act could reduce the value of the 340B drug discount for safety net providers by as much as $1 billion in the first year, an analysis by the 340B Health association suggests.